HHS Shoots Down Call to Use March-In Rights for Xtandi

In a win for Pfizer and Astellas, the US Department of Health and Human Services decided against using march-in rights to lower the price of Xtandi, a blockbuster prostate cancer drug. Exercising march-in rights would the government to share patents made using public funds with third-party manufacturers if a drug is difficult to access and is priced too high.

According to Reuters, “The Department of Health and Human Services (HHS) also denied a petition for a congressional hearing concerning potential price gouging on the drug, Representative Lloyd Doggett, the top Democrat on the House’s Ways and Means Health Subcommittee, said in a statement.”

To read more, click here.

(Source: Reuters, March 22^nd, 2023)